NORTHAMPTON, MA / ACCESSWIRE / January 4, 2024 / Quest Diagnostics recently provided no-cost Blueprint for Wellness® testing to more…
BRENTWOOD, TN / ACCESSWIRE / January 4, 2024 / Odyssey Behavioral Healthcare, a leading provider of mental health, addiction, and…
New patent issued for core rare disease target indication for crofelemerJaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the…
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has…
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the…
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and…
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment…
VILNIUS, LITHUANIA / ACCESSWIRE / December 20, 2023 / From developing healthcare systems to personalized fitness apps such as Joggo,…
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer…
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents…